JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jager, P. L.
Right arrow Articles by Piers, D. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jager, P. L.
Right arrow Articles by Piers, D. A.
Journal of Nuclear Medicine Vol. 42 No. 4 579-585
© 2001 by Society of Nuclear Medicine


CLINICAL INVESTIGATIONS

L-3-[123I]Iodo-{alpha}-Methyl-Tyrosine SPECT in Non–Small Cell Lung Cancer: Preliminary Observations

Pieter L. Jager, Harry J.M. Groen, Annija van der Leest, John W.G. van Putten, Remge M. Pieterman, Elisabeth G.E. de Vries and D. Albertus Piers

PET Center and Departments of Nuclear Medicine, Pulmonary Diseases, Radiotherapy, and Medical Oncology, University Hospital Groningen, Groningen, The Netherlands

L-3-[123I]iodo-{alpha}-methyl-tyrosine (IMT) is a modified amino acid that is avidly taken up by many tumors. Uptake is based on the increased transmembrane transport of amino acids in malignancies. IMT is the only amino acid tracer suitable for SPECT. The aim of this study was to determine the feasibility of IMT SPECT in the detection, staging, and treatment evaluation of non–small cell lung cancer. Methods: We evaluated 44 IMT SPECT studies in 17 patients with histologically proven non–small cell lung cancer, stage III. IMT SPECT and planar imaging of the chest was performed before, 2 wk after, and 3 mo after 60 Gy radiotherapy. Staging was based on the findings of bronchoscopy, chest CT, mediastinoscopy, or explorative thoracotomy. After radiotherapy, CT and bronchoscopy were repeated to assess tumor response. Results: In 15 of 16 evaluable primary tumors, avid IMT uptake was present (sensitivity, 94%), with a mean (±SD) tumor-to-background ratio (T/B) of 2.95 ± 0.78 (range, 1.7–4.9). In 12 of 14 patients (86%) with mediastinal involvement, IMT SPECT detected one or more mediastinal metastases. However, only 13 of 20 mediastinal metastases were detected in lesion analysis (lesion-based sensitivity, 65%). For lesions < 2 cm in diameter, sensitivity was 42%. FDG PET (available for 5 patients) detected more known and unknown lesions than did IMT SPECT. After radiotherapy, T/B had fallen to 1.84 ± 0.29 (P < 0.001 vs. baseline), and 3 mo later to 1.61 ± 0.41 (not statistically significant vs. second study). Considerable nonspecific uptake was found in irradiated normal lung tissue (mean ratio to nonirradiated tissue, 1.79 ± 0.53), persisting for > 3 mo. No relationship was observed between various IMT uptake parameters and the presence of residual viable tumor tissue or survival. Conclusion: IMT SPECT has a high sensitivity for the detection of primary non–small cell lung cancer. Although patient-based sensitivity in detecting mediastinal spread was adequate, sensitivity for individual lesions, especially for small metastases (<2 cm in diameter) was too low to be clinically helpful. Radiotherapy caused considerable nonspecific IMT uptake, which also limits applicability in evaluating the results of treatment.

Key Words: 123I-methyl-tyrosine • lung cancer • mediastinal staging • SPECT • treatment evaluation




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
K. Kaira, N. Oriuchi, Y. Otani, K. Shimizu, S. Tanaka, H. Imai, N. Yanagitani, N. Sunaga, T. Hisada, T. Ishizuka, et al.
Fluorine-18-{alpha}-Methyltyrosine Positron Emission Tomography for Diagnosis and Staging of Lung Cancer: A Clinicopathologic Study
Clin. Cancer Res., November 1, 2007; 13(21): 6369 - 6378.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
P. L. Jager
Improving Amino Acid Imaging: Hungry or Stuffed?
J. Nucl. Med., September 1, 2002; 43(9): 1207 - 1209.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2001 by the Society of Nuclear Medicine.